Raymond James reiterates Dianthus stock Strong Buy on competitor setback

Raymond James reiterated a Strong Buy on Dianthus Therapeutics with a $125 price target after Sanofi stopped its Phase 3 riliprubart study in refractory CIDP due to an interim readout suggesting lack of efficacy. The setback removes a key competitor for Dianthus’s claseprubart and improves the company’s path to a potential sBLA filing in CIDP. Sanofi is still near its 52-week low at $43.69, while the news is likely to be supportive for DNTH rather than broad market-moving.

Analysis

This is a meaningful relative-value reset in rare-disease immunology: the competitive bar for DNTH just dropped because the market has effectively lost one of the better-capitalized alternative paths to CIDP approval. That matters less for near-term read-through on the class and more for financing optionality — a cleaner lane to approval tends to re-rate a single-asset biotech faster than incremental clinical de-risking alone, especially when the remaining competitor is still at a pre-readout stage.

The second-order effect is that Sanofi’s setback may compress partnership appetites across adjacent complement programs, because BD teams will now scrutinize not just efficacy but how quickly a differentiated antibody can translate into registrational signal. For DNTH, the important question is whether higher potency actually converts into fewer failures in placebo-controlled design; if Part A already supported a stronger exposure-response, the probability-weighted value of the Phase 3 step-up rises meaningfully over the next 3-6 months. The key risk is that the market may extrapolate too aggressively from a competitor miss to DNTH success, when CIDP is still a heterogeneous biology and the trial readout could be more sensitive to patient selection and endpoint noise than to pure potency.

For SNY, this is likely a sentiment overhang rather than a fundamental damage event unless the second CIDP program also disappoints. The stock may absorb the news because of diversified earnings power, but the market could shave some probability-weighted pipeline value and penalize management credibility around rare-disease execution for several weeks. Contrarianly, the downside in SNY may be limited if investors view the asset as non-core and if the company can reallocate capital toward higher-conviction launches; the bigger concern is not one failed study, but whether this is the first sign of a broader R&D productivity discount building into the franchise.

Key Decisions for Investors

• Go long DNTH vs short SNY for a 1-3 month relative-value trade; the setup favors DNTH re-rating on improved approval odds while SNY carries reputational and pipeline overhang risk. Size modestly because DNTH remains binary into Phase 3.
• Add DNTH on pullbacks ahead of the next clinical update window; use a 6-12 month horizon and target a re-rating toward the high end of small-cap biotech comparable multiples if data remain clean. Risk/reward is attractive if the market starts pricing in earlier approval probability.
• Avoid chasing SNY weakness outright; any short in SNY should be paired or hedged because the core pharma cash flow likely cushions the move. Best expression is a limited-duration hedge via puts around the next catalyst cluster rather than a structural short.
• If you already own DNTH, finance upside with call spreads rather than outright shares into the readout period to cap event risk while preserving convexity. This is the cleanest way to express a higher-probability competitive win without taking full binary exposure.